Stocks making the biggest moves after hours: Workday, CrowdStrike, Horizon Therapeutics and more

CrowdStrike IPO June 12, 2019 on Nasdaq Exchange.

Source: Nasdaq

Check out the companies making headlines in after-hours trading.

working day — The Workday gained 6% in the postmarket on Tuesday after beating Wall Street estimates on both the top and bottom lines. The software vendor reported adjusted earnings of 99 cents per share on $1.6 billion in revenue, where analysts polled by Refinitiv expected 84 cents per share and adjusted earnings of $1.59 billion in revenue.

Related Investment News

Pro Picks: Watch all of Tuesday's big stock calls on CNBC

cnbc pro

crowdstrike — CrowdStrike Holdings reported a plunge of more than 18% after light guidance for fourth-quarter revenue. In the just-concluded quarter, results topped earnings and revenue expectations, with the cybersecurity provider posting adjusted earnings of 40 cents per share on $581 million in revenue, where analysts were expecting 31 cents per share on $574 million in Refinitiv revenue. Adjusted earnings of cents were expected.

NetApp — NetApp stock plunged 10.8% after the cloud services and data management provider posted weaker-than-expected revenue in its latest quarter. NetApp reported adjusted earnings per share of $1.48, beating estimates of $1.33. But its $1.66 billion in revenue fell short of the $1.68 billion Wall Street estimated, according to Refinitiv. NetApp also issued weak forward guidance.

hp enterprise — HP Enterprise rose 2.2% after the company beat earnings estimates on the top and bottom lines. Per Refinitiv, HPE adjusted earnings per share at 57 cents on $7.87 billion in revenue topped Wall Street estimates of 56 cents and $7.42 billion, respectively.

AST Spacemobile Shares of AST Spacemobile plunged 10.7% after the satellite maker announced plans to sell $65 million of Class A common stock. The proceeds will be used for general corporate purposes.

Horizon Therapeutics — The biotech soared 36% in the hours after the Dow Jones reported that the $18 billion biotech is generating acquisition interest. Dow Jones cited unnamed people familiar with the matter.